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technique is regarded as the most accurate calculation 
method in the dose calculations for kV beams. The Monte 
Carlo user code, BEAMnrc/DOSXYZnrc was used to simulate x-
ray sources. The detailed x-ray tube geometry was simulated, 
including the anode x-ray tube specifications, target design, 
beam definition, beam filtration systems, and incident 
electron energy. Each simulated realistic kV beam with 
respect of an image acquisition procedure was stored in a 
phase-space file. The simulated beam specific to an image 
procedure was individually calibrated by using anl ion 
chamber in which the air kerma calibration factor is 
traceable to national standards. When a Monte Carlo 
simulated beam is calibrated it allows the user to calculate 
both relative and absolute absorbed doses to patients. 
Patient dose calculations were done using the Monte Carlo 
generated kV beam as an incident beam on patient CT based 
images. The dose resulting from a radiograph image 
procedure was calculated by incident the source from a fixed 
incident angle (AP, RL, etc.) while the dose resulting from a 
kV-CBCT scan was calculated by rotating the X-ray source 
around the patient based on the specific scan procedure. 
Results: The Monte Carlo simulation provides realistic beam 
details such as energy spectra, particle fluence, and the 
mean energy distributions. The simulation accuracy was 
validated by benchmarking the Monte Carlo simulations 
against measurements of the beam’s half-value layers and 
dose distributions. Patient dose calculations showed that the 
imaging doses to the eyes for representative head images are 
0.05-0.2 cGy and 0.1 cGy; doses to the bladder for 
representative pelvis images are 1.6 cGy and 0.07 cGy; while 
doses to the heart for representative thorax images are 0.4 
cGy and 0.07 cGy; when using kV-CBCT scans and kV 
radiographs, respectively. In contrast, organ doses increase 
by a factor of 2-4 if bow-tie filters are not used during kV-
CBCT acquisitions.   
Conclusion: The excellent agreement between Monte Carlo 
calculations and measurements demonstrates that Monte 
Carlo techniques yield accurate results for kV dose 
calculations. Current on-board kV imaging devices result in 
much lower imaging doses compared to the conventional MV 
portal imagers. There are a variety of approaches available 
to significantly reduce the image doses. It is feasible to 
estimate and account for organ dose by using tabulated 
values based on scan procedure and site because organ doses 
from imaging procedures are only modestly dependent upon 
scan location and body size.   
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Since the prostate-specific membrane antigen (PSMA) is 
frequently over-expressed in prostate cancer (PCa) several 
PSMA-targeting molecules are under development to detect 
and treat metastatic castration resistant prostate cancer. 
In 82.8% of 319 patients investigated with 68Ga-PSMAHBED-
PET/CT at least one lesion indicative for PCa was detected. 
Tumor detection was positively associated with PSA level and 
androgen deprivation therapy. Amongst lesions investigated 
by histology, 30 were false-negative in 68Ga-PSMAHBED-PET/CT 
(one local relapse in one patient and 29 lymph nodes in 
another patient), all other lesions (n=416) were diagnosed 
true-positive or -negative. Fifty of 116 patients available for 
follow-up received local therapy after 68Ga-PSMAHBED-PET/CT.  
A comparison of 68Ga-PSMA-ligand with 18F-
fluoromethylcholine PET/CT revealed 78 PC-suspicious lesions 
in 32 patients using 68Ga-PSMA-PET/CT and 56 lesions in 26 
patients using Choline-PET/CT. The higher detection rate in 
68Ga-PSMA-PET/CT concerning PC-suspicious lesions was 
significant (p=0.04). All lesions detected by 18F-
fluoromethylcholine-PET/CT were also seen by 68Ga-PSMA-
PET/CT. In 68Ga-PSMA-PET/CT SUVmax was clearly (>10%) 
higher in 62 of 78 lesions (79.1%) and tumor-to-background 
ratio was clearly (>10%) higher in 73 of 78 lesions (93.6%) 
when compared to 18F-fluoromethylcholine-PET/CT.  
Since the ligand bound to PSMA is internalized, the target 
may also be used for endoradiotherapy. We used a small 
molecule inhibitor of PSMA ((S)-2-(3-((S)-1-carboxy-5-(3-(4-
[131I]-iodophenyl)ureido)-pentyl)ureido)-pentanedioic-acid; 
MIP-1095) for therapy in men with mCRPC. Dosimetry 
estimates for I-131-MIP-1095 revealed that the highest 
absorbed doses were delivered to the salivary glands (3.8 
mSv/MBq, liver (1.7 mSv/MBq) and kidneys (1.4 mSv/MBq). 
The absorbed dose calculated for the red marrow was 0.37 
mSv/MBq. PSA values decreased by >50% in 60.7% of the men 
treated. 84.6 % of men with bone pain showed complete or 
moderate reduction in pain. Hematological toxicities were 
mild. 25% of men treated had a transient slight to moderate 
dry mouth. No adverse effects on renal function were 
observed. 
In order to increase the therapeutic flexibilty we designed a 
novel theranostic PSMA ligand coupled to DOTA which allows 
coupling to Ga-68 for diagnostic use or to Lu-177 or Ac-225 
for therapy. Especially for alpha therapy with Ac-225 
promising results were found in the first 10 patients.  
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The integration of the full analytical power of today’s multi-
modal and multi-parametric imaging techniques into 
workflows of radiation oncology has not yet reached daily 
clinical routine. Reasons for this are manifold and range from 
simple data integration problems to the question, how the 
relevant information distributed over different images or 
over several parameters can be fused in the best way to 
provide a more complete and comprehensive image of the 
current situation. 
The EU project Software for the Use of Multi-Modality images 
in External Radiotherapy – SUMMER(*) is addressing these 
problems with the aim to extend the current set of imaging 
modalities integrated into radiotherapy planning. In this talk, 
I will give an overview over faced challenges and results 
achieved over the last 3 years from a Visual Computing 
perspective. I will show how visualization, data fusion, and 
alternative ways in data representation can be used to gain 
